98 related articles for article (PubMed ID: 12215271)
21. Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells.
Gilligan MG; Knox P; Weedon S; Barton R; Kerr DJ; Searle P; Young LS
Gene Ther; 1998 Jul; 5(7):965-74. PubMed ID: 9813668
[TBL] [Abstract][Full Text] [Related]
22. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial.
Navabi H; Croston D; Hobot J; Clayton A; Zitvogel L; Jasani B; Bailey-Wood R; Wilson K; Tabi Z; Mason MD; Adams M
Blood Cells Mol Dis; 2005; 35(2):149-52. PubMed ID: 16061407
[TBL] [Abstract][Full Text] [Related]
23. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene.
Tai YT; Strobel T; Kufe D; Cannistra SA
Cancer Res; 1999 May; 59(9):2121-6. PubMed ID: 10232598
[TBL] [Abstract][Full Text] [Related]
24. Long-term transgene expression in cardiac and skeletal muscle following fetal administration of adenoviral or adeno-associated viral vectors in mice.
Bouchard S; MacKenzie TC; Radu AP; Hayashi S; Peranteau WH; Chirmule N; Flake AW
J Gene Med; 2003 Nov; 5(11):941-50. PubMed ID: 14601131
[TBL] [Abstract][Full Text] [Related]
25. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase.
Bilsland AE; Anderson CJ; Fletcher-Monaghan AJ; McGregor F; Evans TR; Ganly I; Knox RJ; Plumb JA; Keith WN
Oncogene; 2003 Jan; 22(3):370-80. PubMed ID: 12545158
[TBL] [Abstract][Full Text] [Related]
26. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile.
Horton HM; Dorigo O; Hernandez P; Anderson D; Berek JS; Parker SE
J Immunol; 1999 Dec; 163(12):6378-85. PubMed ID: 10586027
[TBL] [Abstract][Full Text] [Related]
27. An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer.
Arafat WO; Gómez-Navarro J; Xiang J; Barnes MN; Mahasreshti P; Alvarez RD; Siegal GP; Badib AO; Buchsbaum D; Curiel DT; Stackhouse MA
Mol Ther; 2000 Jun; 1(6):545-54. PubMed ID: 10933979
[TBL] [Abstract][Full Text] [Related]
28. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
Peng XY; Won JH; Rutherford T; Fujii T; Zelterman D; Pizzorno G; Sapi E; Leavitt J; Kacinski B; Crystal R; Schwartz P; Deisseroth A
Cancer Res; 2001 Jun; 61(11):4405-13. PubMed ID: 11389068
[TBL] [Abstract][Full Text] [Related]
29. CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscle.
Jiang Z; Schiedner G; Gilchrist SC; Kochanek S; Clemens PR
Gene Ther; 2004 Oct; 11(19):1453-61. PubMed ID: 15269713
[TBL] [Abstract][Full Text] [Related]
30. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration.
Tong XW; Block A; Chen SH; Contant CF; Agoulnik I; Blankenburg K; Kaufman RH; Woo SL; Kieback DG
Gynecol Oncol; 1996 May; 61(2):175-9. PubMed ID: 8626129
[TBL] [Abstract][Full Text] [Related]
31. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
[TBL] [Abstract][Full Text] [Related]
32. From gene therapy to virotherapy for ovarian cancer.
Stoff-Khalili MA; Dall P; Curiel DT
Minerva Ginecol; 2004 Dec; 56(6):503-14. PubMed ID: 15729203
[TBL] [Abstract][Full Text] [Related]
33. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma.
Barker SD; Dmitriev IP; Nettelbeck DM; Liu B; Rivera AA; Alvarez RD; Curiel DT; Hemminki A
Gene Ther; 2003 Jul; 10(14):1198-204. PubMed ID: 12833129
[TBL] [Abstract][Full Text] [Related]
34. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.
Alvarez RD; Barnes MN; Gomez-Navarro J; Wang M; Strong TV; Arafat W; Arani RB; Johnson MR; Roberts BL; Siegal GP; Curiel DT
Clin Cancer Res; 2000 Aug; 6(8):3081-7. PubMed ID: 10955787
[TBL] [Abstract][Full Text] [Related]
35. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.
Isayeva T; Ren C; Ponnazhagan S
Clin Cancer Res; 2005 Feb; 11(3):1342-7. PubMed ID: 15709207
[TBL] [Abstract][Full Text] [Related]
36. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma.
Mujoo K; Maneval DC; Anderson SC; Gutterman JU
Oncogene; 1996 Apr; 12(8):1617-23. PubMed ID: 8622881
[TBL] [Abstract][Full Text] [Related]
37. Induction of interferon-gamma and tumor necrosis factor in ascites of a patient with ovarian cancer by OK-432.
Mori H; Itoh N; Shiraki S; Tamaya T
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Apr; 40(4):497-8. PubMed ID: 3131464
[No Abstract] [Full Text] [Related]
38. PEGylated adenovirus for targeted gene therapy.
O'Riordan CR; Song A
Methods Mol Biol; 2008; 434():133-60. PubMed ID: 18470643
[TBL] [Abstract][Full Text] [Related]
39. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig.
Jooss K; Turka LA; Wilson JM
Gene Ther; 1998 Mar; 5(3):309-19. PubMed ID: 9614550
[TBL] [Abstract][Full Text] [Related]
40. Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer.
Provencher DM; Finstad CL; Saigo PE; Rubin SC; Hoskins WJ; Federici MG; Stockert E; Lloyd KO; Lewis JL
Gynecol Oncol; 1993 Jul; 50(1):78-83. PubMed ID: 8349167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
